# ETX-197

Source: https://onco.cc/drugs/etx-197/  
OnCo record `etx-197` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ETX-197 is an experimental small molecule from Ensem Therapeutics, in preclinical development for solid tumours with cyclin E amplification.

## Summary

ETX-197 is a small molecule (oral) from Ensem Therapeutics. An oral CDK2 inhibitor, which the company believes could treat tumours with cyclin E amplification and cancers that have become resistant to standard treatment through CDK2 dysregulation. Its furthest stage is preclinical development, for solid tumours with cyclin E amplification. No clinical trial naming it is registered on ClinicalTrials.gov. No ClinicalTrials.gov record for ETX-197. The pipeline chart's stage is graphical only (bar not readable as text); 'preclinical' follows OnCo's text and the absence of a registered trial, not a stated source. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: ETX-197
- Modality: Small molecule (oral)
- Mechanism: An oral CDK2 inhibitor, which the company believes could treat tumours with cyclin E amplification and cancers that have become resistant to standard treatment through CDK2 dysregulation.

## Sources

- Ensem Therapeutics: ensemtx.com: https://ensemtx.com/science/pipeline/

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [CDK2](https://onco.cc/targets/cdk2/)
- companies: [Ensem Therapeutics](https://onco.cc/companies/ensem-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/etx-197.json